Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of "Hold" by Analysts

Key Points

• Sutro Biopharma, Inc. is currently rated with an average of "Hold" by analysts, with two sell ratings, four hold ratings, and two buy ratings among the eight analysts covering the stock.
• The company's shares recently experienced a significant increase of 14.7%, opening at $1.01, but have a 12-month low of $0.52 and a high of $4.60.
• In recent insider transactions, Director Connie Matsui purchased 50,000 shares at $0.80 per share, indicating confidence in the company amidst ongoing analyst evaluations.

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) have earned a consensus rating of "Hold" from the eight analysts that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $4.4667.

A number of equities analysts recently weighed in on STRO shares. Wells Fargo & Company lowered their target price on shares of Sutro Biopharma from $4.00 to $3.00 and set an "equal weight" rating for the company in a research note on Tuesday, August 12th. Wall Street Zen raised shares of Sutro Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, September 13th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Sutro Biopharma in a report on Wednesday, October 8th.

Sutro Biopharma Stock Up 14.7%

Shares of NASDAQ STRO opened at $1.01 on Friday. Sutro Biopharma has a twelve month low of $0.52 and a twelve month high of $4.60. The firm has a fifty day simple moving average of $0.88 and a 200 day simple moving average of $0.84. The company has a market capitalization of $85.62 million, a PE ratio of -0.40 and a beta of 1.61.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $0.25. Sutro Biopharma had a negative net margin of 201.32% and a negative return on equity of 852.70%. The business had revenue of $63.74 million during the quarter, compared to the consensus estimate of $14.55 million. As a group, equities analysts expect that Sutro Biopharma will post -2.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Connie Matsui purchased 50,000 shares of Sutro Biopharma stock in a transaction on Wednesday, October 15th. The stock was acquired at an average cost of $0.80 per share, for a total transaction of $40,000.00. Following the completion of the acquisition, the director owned 50,000 shares of the company's stock, valued at $40,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have acquired 111,754 shares of company stock valued at $89,601 in the last ninety days. Company insiders own 3.60% of the company's stock.

Institutional Investors Weigh In On Sutro Biopharma

A number of large investors have recently bought and sold shares of the stock. CWM LLC grew its holdings in Sutro Biopharma by 73.2% in the second quarter. CWM LLC now owns 56,657 shares of the company's stock worth $40,000 after purchasing an additional 23,941 shares during the period. Vontobel Holding Ltd. grew its holdings in shares of Sutro Biopharma by 100.0% during the first quarter. Vontobel Holding Ltd. now owns 50,000 shares of the company's stock valued at $33,000 after buying an additional 25,000 shares during the last quarter. Vestal Point Capital LP grew its holdings in shares of Sutro Biopharma by 1.2% during the first quarter. Vestal Point Capital LP now owns 2,600,000 shares of the company's stock valued at $1,692,000 after buying an additional 30,000 shares during the last quarter. Catalyst Funds Management Pty Ltd acquired a new position in shares of Sutro Biopharma during the second quarter valued at about $27,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of Sutro Biopharma by 174.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company's stock valued at $43,000 after buying an additional 38,561 shares during the last quarter. 96.99% of the stock is currently owned by institutional investors and hedge funds.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.